You searched for rivaroxaban - Page 3 of 15 - MPR

Your search for rivaroxaban returned 141 results

Your search for rivaroxaban returned 141 results

Sort Results:

Relevant Recent
American College of Cardiology 2013

Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients

After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Drugs in the Pipeline

Phase 3 Study of Xarelto for Treatment and Secondary Prevention of Venous Blood Clots

Janssen Research & Development announced results of the EINSTEIN-PE study showing that Xarelto (rivaroxaban) was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).

Xarelto Approved for Prevention of DVT

Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.
Clinical Charts

Anticoagulant Dosing Conversions

Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.

COMPASS Trial Ending Early After Reaching Superiority Endpoint

Janssen announced that the Phase 3 trial, COMPASS, is stopping earlier than planned based on the recommendation of the study's Independent Data Monitoring Committee (DMC), as the primary major adverse cardiovascular events (MACE) endpoint has reached its pre-specified criteria for superiority.